Nuvectis Pharma, Inc. (NVCT)
NVCT moved a median of -0.24% 30 minutes after news, and -0.78% by the close. How NVCT actually reacts to news — the realized, point-in-time move the market made, measured across 166 labeled events over the last three years with zero look-ahead.
NVCT’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 40% | 157 |
| 30-min | -0.24% | 43% | 162 |
| 60-min | -0.34% | 41% | 165 |
| to close | -0.78% | 47% | 165 |
| Middle 50% of NVCT reactions | -1.43% to +1.61% |
|---|---|
| Median reaction (30-min) | -0.24% |
| Measured reactions | 166 |
Half of all Nuvectis Pharma, Inc. news events land between -1.43% and +1.61% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How NVCT reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 11 | -0.36% | 46% | +1.32% |
| Rating reiterations | 15 | +0.52% | 53% | -1.05% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how NVCT ranks against every other measured name →
That’s how NVCT usually reacts — get an email when it moves on news →Email me when NVCT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to NVCT's baseline. Nothing else.
Recent NVCT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Nuvectis Pharma to Participate in the Maxim Growth Summit 2026 | Press release | GlobeNewswire | -1.17% | +5.02% | |
| Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma | Press release | GlobeNewswire | +1.54% | +1.17% | |
| Nuvectis Pharma To Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -1.46% | +1.54% | |
| Form EFFECT Nuvectis Pharma, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +2.98% | -3.36% | |
| Form 8-K Nuvectis Pharma, Inc. For: Jul 20 | SEC filing · Form 8-K | SEC EDGAR | -0.95% | +1.32% | |
| Form S-3 Nuvectis Pharma, Inc. | SEC filing · Form S-3 | SEC EDGAR | -0.95% | +1.32% | |
| Form 10-Q Nuvectis Pharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.22% | +4.36% | |
| Form 8-K Nuvectis Pharma, Inc. For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | -3.22% | +4.36% | |
| Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights | Press release | GlobeNewswire | -3.22% | +4.36% | |
| Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors | Press release | GlobeNewswire | -1.30% | +4.46% | |
| Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors | Press release | GlobeNewswire | -1.30% | +4.46% | |
| Form 8-K Nuvectis Pharma, Inc. For: Jun 29 | SEC filing · Form 8-K | SEC EDGAR | +3.60% | +4.89% | |
| Form 8-K Nuvectis Pharma, Inc. For: Jun 29 | SEC filing · Form 8-K | SEC EDGAR | -1.92% | -11.71% | |
| Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock | Press release | GlobeNewswire | -1.92% | -11.71% | |
| Nuvectis Pharma Announces Proposed Public Offering of Common Stock | Press release | GlobeNewswire | -1.92% | -11.71% | |
| Form 8-K Nuvectis Pharma, Inc. For: Jun 22 | SEC filing · Form 8-K | SEC EDGAR | +1.81% | +9.48% | |
| Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds | Press release | GlobeNewswire | +4.70% | +19.44% | |
| Form 8-K Nuvectis Pharma, Inc. For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.92% | |
| Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ | Press release | GlobeNewswire | +1.08% | +3.15% | |
| Form 10-Q Nuvectis Pharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.79% | +9.35% | |
| Form 8-K Nuvectis Pharma, Inc. For: May 05 | SEC filing · Form 8-K | SEC EDGAR | +0.79% | +9.35% | |
| Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights | Press release | GlobeNewswire | +0.79% | +9.35% | |
| Form DEF 14A Nuvectis Pharma, Inc. For: Jun 11 | SEC filing · Form DEF | SEC EDGAR | +0.00% | -1.25% | |
| Form DEFA14A Nuvectis Pharma, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | -1.25% | |
| Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting | Press release | GlobeNewswire | +0.00% | +1.71% | |
| Form EFFECT Nuvectis Pharma, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +1.55% | |
| Form S-3 Nuvectis Pharma, Inc. | SEC filing · Form S-3 | SEC EDGAR | -2.30% | +2.88% | |
| Form 10-K Nuvectis Pharma, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.13% | -0.79% | |
| Form 8-K Nuvectis Pharma, Inc. For: Feb 11 | SEC filing · Form 8-K | SEC EDGAR | -1.13% | -0.79% | |
| Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights | Press release | GlobeNewswire | -1.13% | -0.79% | |
| Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC | Press release | GlobeNewswire | +0.00% | -1.17% | |
| Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC | Press release | GlobeNewswire | -0.35% | +1.33% | |
| CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights | Press release | GlobeNewswire | -2.33% | -5.31% | |
| Form 10-Q Nuvectis Pharma, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.33% | -5.31% | |
| Form 8-K Nuvectis Pharma, Inc. For: Nov 04 | SEC filing · Form 8-K | SEC EDGAR | -2.33% | -5.31% | |
| Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights | Press release | GlobeNewswire | -2.33% | -5.31% | |
| Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics | Press release | GlobeNewswire | -1.59% | +3.97% | |
| Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Form 8-K Nuvectis Pharma, Inc. For: Sep 22 | SEC filing · Form 8-K | SEC EDGAR | +1.27% | +0.68% | |
| Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors | Press release | GlobeNewswire | +1.27% | +0.68% | |
| Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference | Press release | GlobeNewswire | +1.88% | +2.03% | |
| Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900 | Press release | GlobeNewswire | +2.76% | — | |
| Form 10-Q Nuvectis Pharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.28% | -3.63% | |
| Form 8-K Nuvectis Pharma, Inc. For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | +0.28% | -3.63% | |
| Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights | Press release | GlobeNewswire | +0.28% | -3.63% | |
| Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study | Press release | GlobeNewswire | +4.42% | +4.19% | |
| Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies | Press release | GlobeNewswire | -1.77% | -4.29% | |
| Form 8-K Nuvectis Pharma, Inc. For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | — | +2.73% | |
| Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference | Press release | GlobeNewswire | +1.91% | +9.83% | |
| Form 8-K Nuvectis Pharma, Inc. For: May 09 | SEC filing · Form 8-K | SEC EDGAR | -3.63% | -6.42% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the NVCT section they belong to.
Where else NVCT is measured.
NVCT earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Nuvectis Pharma, Inc.'s median reaction calculated?
Every labeled NVCT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 166 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 43% of NVCT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does NVCT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.